TORONTO, Feb. 28, 2017 /PRNewswire/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] isresponding to a higher than average trading volume in the Company's shares today. Merus is aware of a news story from Reuters suggesting that it has hired Rothschild & Co. to explore strategic alternatives.
The Company is currently using
Investors are cautioned that the engagement of a financial advisor should not be viewed as an indication that any specific process or transaction will be pursued. Merus does not intend to comment further except as required by applicable securities laws or the policies of the Toronto Stock Exchange.
About Merus Labs
Merus Labs is a specialty pharmaceutical company focused on acquiring and optimizing established and growth products. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.
Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements include statements relating to the Company's future business and operating plans, including potential changes to capital structure, product acquisitions or prospective corporate transactions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results expressed or implied by these statements. Such factors include the following: general economic and business conditions, changes in demand for Merus' products, changes in competition, the ability of Merus to integrate acquisitions or complete future acquisitions, Merus' ability to complete any financing, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. Investors should refer to the Company's MD&A, Annual Information Form and Annual Report on 40-F for the year ended September 30, 2016 for a more comprehensive discussion of the risks that are material to the Company and its business. These forward-looking statements speak only as of the date of this press release, and Merus undertakes no obligation to update or revise the statements.
SOURCE Merus Labs International Inc.
Subscribe to our Free Newsletters!
Cardiopulmonary bypass is a technique which allows performing open heart surgical procedures in a ...
Acyclovir is an effective antiviral medication used primarily for treating the symptoms of herpes ...
Fasciotomy is a surgical procedure where the fascia is incised to relieve the compartmental ...View All